Online inquiry

IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6363MR)

This product GTTS-WQ6363MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets MSTN gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_005259.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2660
UniProt ID O14793
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6363MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14657MR IVTScrip™ mRNA-Anti-DPEP3, SC-003 mAb(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SC-003 mAb
GTTS-WQ15073MR IVTScrip™ mRNA-Anti-KDR, SSS-23(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SSS-23
GTTS-WQ13783MR IVTScrip™ mRNA-Anti-MSTN, REGN-1033(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA REGN-1033
GTTS-WQ9649MR IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA JNJ-64007957
GTTS-WQ10386MR IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA LY2127399
GTTS-WQ8608MR IVTScrip™ mRNA-Anti-CD33, HuM195(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HuM195
GTTS-WQ2153MR IVTScrip™ mRNA-Anti-IL6, ALD-518(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ALD-518
GTTS-WQ13880MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA REGN-1979
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW